Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21932035 | 0.99 | BACE1 (0.36) | BACE1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2571337 | 0.91 | SMN1; SMN2 (0.39) | BACE1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2571341 | 0.91 | SMN1; SMN2 (0.39) | BACE1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21932023 | 0.90 | KMT2A (0.38) | BACE1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2572674 | 0.90 | SMN1; SMN2 (0.42) | BACE1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2572672 | 0.90 | SMN1; SMN2 (0.42) | BACE1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL28547555 | 0.90 | BACE1 (0.38) | BACE1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3150809 | 0.89 | POLB (0.41) | BACE1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3150802 | 0.89 | POLB (0.41) | BACE1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21932025 | 0.89 | RXFP1 (0.35) | BACE1KMT2AMEN1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12473377-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-11987558-B1 | ALK5 inhibitors and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | SYNTHIS THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-20210299268-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210299268-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3820467-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | Synthis Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020256751-A1 | ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS, LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020256721-A1 | ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS, LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200147234-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS, LLC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200147234-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS, LLC (US) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473377-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | BACE1 3532/4885KMT2A 494/4885MEN1 2875/4885 |
| US-11987558-B1 | ALK5 inhibitors and their uses | ALK, ALKBH3, ALKBH5 | BACE1 2275/4885KMT2A 624/4885MEN1 2884/4885 |
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | BACE1 3532/4885KMT2A 494/4885MEN1 2875/4885 |
| US-20210299268-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | BACE1 3532/4885KMT2A 494/4885MEN1 2875/4885 |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | ALK, ALKBH5, ALKBH3 | BACE1 3899/4885KMT2A 540/4885MEN1 2877/4885 |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | BACE1 3532/4885KMT2A 494/4885MEN1 2875/4885 |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, CD2, TGFBR2 | BACE1 1025/4885KMT2A 1567/4885MEN1 3141/4885 |
| US-20200147234-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | BACE1 3532/4885KMT2A 494/4885MEN1 2875/4885 |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | BACE1 3532/4885KMT2A 494/4885MEN1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.